

Electronic Acknowledgement Receipt

EFS ID:	10861912
Application Number:	10562383
International Application Number:	
Confirmation Number:	3836
Title of Invention:	Methods and Nucleic Acids for Analyses of Colorectal Cell Proliferative Disorders
First Named Inventor/Applicant Name:	Cathy Lofton-Day
Customer Number:	28213
Filer:	Lisa A. Haile/Ann Kopels
Filer Authorized By:	Lisa A. Haile
Attorney Docket Number:	EPIGEN1470
Receipt Date:	01-SEP-2011
Filing Date:	13-JUN-2007
Time Stamp:	13:36:50
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$470
RAM confirmation Number	23679
Deposit Account	071896
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1		EOT_1_RCE_RESPONSE_IDS_SB08.pdf	1618312 900075404ffffbcf9c7e6121e718a6874412 218	yes	31
Multipart Description/PDF files in .zip description					
Document Description		Start		End	
Extension of Time		1		1	
Request for Continued Examination (RCE)		2		2	
Amendment After Final		3		3	
Claims		4		15	
Applicant Arguments/Remarks Made in an Amendment		16		26	
Transmittal Letter		27		28	
Information Disclosure Statement (IDS) Form (SB08)		29		31	

Warnings:

Information:

2	Foreign Reference	EPIGEN1470_IDS_AA_.pdf	2991078 8944d405764851d194c587d8ae0d5fda479 2bc3c	no	56
---	-------------------	------------------------	---	----	----

Warnings:

Information:

3	Non Patent Literature	AB_AZ465273_2000_XP002638249_.pdf	58067 2455af5266789e86faf751f1648df5ab60e99 4fc	no	1
---	-----------------------	-----------------------------------	---	----	---

Warnings:

Information:

4	Non Patent Literature	AC_AAF05507_2001_XP002638234_.pdf	32424 bdb8328b68ef1eac1e59e58d27fb652dbe 56e50	no	1
---	-----------------------	-----------------------------------	--	----	---

Warnings:

Information:

5	Non Patent Literature	AD_AAF99133_2001_XP00263 8260_.pdf	47701 2725473c1dd31fc54554fdad3138ab0b257 3c97	no	1
Warnings:					
Information:					
6	Non Patent Literature	AE_AK055051_2001_XP002638 259_.pdf	172100 7cb05bd2279934e1dfe4268cc38877f91b9f b8e6	no	2
Warnings:					
Information:					
7	Non Patent Literature	AF_ABL35101_2002_XP002638 044_.pdf	49167 09c089192cce4a8f7820092de8487886a2c2 04fd	no	1
Warnings:					
Information:					
8	Non Patent Literature	AG_ABQ17626_2002_XP00263 8000_.pdf	76453 bf99f16df05fb9503281907a554844588f36 a0c	no	1
Warnings:					
Information:					
9	Non Patent Literature	AH_ABQ43830_2002_XP00263 8045_.pdf	76441 a5da752c9fd7d5214d17d0d2bdbf000fda7 ed7b7	no	1
Warnings:					
Information:					
10	Non Patent Literature	AI_ABQ45658_2002_XP002638 046_.pdf	64411 b7957dbad90688ac1cdc6fe15068db314e 46c82	no	1
Warnings:					
Information:					
11	Non Patent Literature	AJ_ABQ43826_2002_XP002638 047_.pdf	64037 270f46cf528d2c526778f3e9c26228d19f6a6 c85	no	1
Warnings:					
Information:					
12	Non Patent Literature	AK_ABX74051_2003_XP002638 248_.pdf	205745 9f2b0050f8796e622e74f6fe91a8ef85205a 0e4	no	3
Warnings:					
Information:					
13	Non Patent Literature	Lofton- Day_2008_DNA_methylation_ biomarkers_.pdf	814186 5680d77e35ca0c72e37c47513a1f49adbc5c 9c16	no	10
Warnings:					
Information:					

14	Non Patent Literature	Rakowicz-Szulcynska_1992_Gamma-interferon-induced_nerve_.pdf	794275 5d76f97f2c5a67e0863e5ccfa3131213f9316805	no	10
Warnings:					
Information:					
15	Foreign Reference	EPIGEN1470_IDS_AN_ESR_.pdf	410597 13144fb9476a41e4facf3d8ff3ec20cfa0c603bd	no	8
Warnings:					
Information:					
16	Foreign Reference	EPIGEN1470_IDS_AO_ESR_.pdf	436922 69bbb1c18203b983889b3ea2640aeeaf6c1c1b2b	no	8
Warnings:					
Information:					
17	Foreign Reference	EPIGEN1470_IDS_AP_ESR_.pdf	387588 3055f78322488353217f537b3220902851efbf7a	no	8
Warnings:					
Information:					
18	Foreign Reference	EPIGEN1470_IDS_AQ_ESR_.pdf	384896 f15f045f745d65c2b9d5ba2637cc9ecd3b86504b	no	8
Warnings:					
Information:					
19	Fee Worksheet (SB06)	fee-info.pdf	32016 05d764b49633593ff0f7d6a01bb9e6563da9316e	no	2
Total Files Size (in bytes):				8716416	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.